Nano Dimension (NNDM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Jun, 2026Executive summary
Murchinson Ltd. and affiliates, holding 7.7% of shares, are soliciting proxies to enact significant governance changes at an extraordinary general meeting, citing underperformance and poor governance.
The meeting agenda includes proposals to declassify the board, require shareholder approval for poison pills and major transactions, remove three directors, and appoint three new nominees.
Murchinson recommends voting for all its proposals, aiming to align the board with shareholder interests and enhance accountability.
Voting matters and shareholder proposals
Proposals include a non-binding advisory vote on the company's strategic alternatives review, declassification of the board, restrictions on poison pills, shareholder approval for major transactions, removal of three directors, and appointment of three new directors.
Each proposal has specific approval thresholds, with most requiring a simple majority, except the board declassification, which requires a 70% majority.
Shareholders can vote by proxy, with detailed procedures for ADS and ordinary share holders.
Board of directors and corporate governance
Proposal to amend Article 39 to declassify the board and require annual director elections.
Proposal to remove directors Robert Pons, Joshua Rosensweig, and David Stehlin, and any new directors appointed after May 21, 2026.
Proposal to appoint Moshe Rozenbaum, Eliezer Eli Tarlow, and Paul Fruchthandler as new directors, who are presented as independent and highly qualified.
Latest events from Nano Dimension
- Shareholders face a pivotal vote on Board control, with future input on strategic transactions.NNDM
Proxy filing10 Jul 2026 - Q3 revenue surged 81% to $26.9M, but margins fell; Q4 guidance: $31.5M–$33.5M.NNDM
Q3 20259 Jul 2026 - Record Q2 revenue, improved margins, and a transformative acquisition highlight best quarter.NNDM
Q2 20248 Jul 2026 - Proxy contest seeks board overhaul, annual elections, and more shareholder control over key decisions.NNDM
Proxy filing30 Jun 2026 - Shareholders will vote on strategic direction, governance amendments, and board composition changes.NNDM
Proxy filing29 Jun 2026 - Board supports strategic review and declassification, opposes governance and director changes.NNDM
Proxy filing25 Jun 2026 - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing17 Jun 2026 - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement16 Jun 2026 - Nano and Infinite plan a merger to create an AI-powered health diagnostics company, pending approvals.NNDM
Proxy filing15 Jun 2026